The Chinese DNA sequencing market is expected to grow from $1.2 billion in 2025 and is projected to reach $3.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 21.5% during the forecast period of 2025 to 2030.
The Chinese DNA sequencing market has seen rapid growth, with next-generation sequencing (NGS) continuing to grow. The demand for precision medicine is a driver of this growth, as is the increased use of DNA sequencing in healthcare, agriculture and research. Continued improvements in sequencing platforms and bioinformatics tools make genomic analysis even faster, more accurate and cheaper, which is fueling advances in oncology diagnostics, reproductive health, infectious disease surveillance, and large-scale population genomics projects. Major companies in the domestic market, including BGI Genomics, Novogene and Berry Genomics, are driving large-scale sequencing projects, and increasing
governmental investments and synergistic collaboration opportunities with hospitals and academia have increased the pace of adoption in the market.
In this report, “China” refers to mainland China and does not include Hong Kong, Macao, or Taiwan. Mainland China has 31 province-level regions, including 22 provinces, four province-level municipalities (cities) and five province-level autonomous regions. Beijing, Shanghai and Guangdong are also discussed in this report.
The report also highlights developments related to venture capital and corporate investments, regulatory trends and enterprise strategies of key firms and potential future opportunities stemming from AI-driven sequences of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis and tariff assessments makes this report a critical resource for stakeholders, investors and policymakers seeking to understand and take advantage of the rapidly developing Chinese DNA sequencing sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking or share of key companies. It also has a dedicated section of company profiles that covers details of leading companies.
The Chinese DNA sequencing market has seen rapid growth, with next-generation sequencing (NGS) continuing to grow. The demand for precision medicine is a driver of this growth, as is the increased use of DNA sequencing in healthcare, agriculture and research. Continued improvements in sequencing platforms and bioinformatics tools make genomic analysis even faster, more accurate and cheaper, which is fueling advances in oncology diagnostics, reproductive health, infectious disease surveillance, and large-scale population genomics projects. Major companies in the domestic market, including BGI Genomics, Novogene and Berry Genomics, are driving large-scale sequencing projects, and increasing
governmental investments and synergistic collaboration opportunities with hospitals and academia have increased the pace of adoption in the market.
Report Scope
This report provides an overview of the Chinese market for DNA sequencing and analyzes market trends. It includes revenue ($ million) for the base year data for 2024 and estimated data for 2025, and compound annual growth rate (CAGR) forecasts through the end of 2030. The market analyzed by products and services, technology, applications, end-users and provinces. The provinces covered in this study include Beijing, Shanghai, Guangdong and others.In this report, “China” refers to mainland China and does not include Hong Kong, Macao, or Taiwan. Mainland China has 31 province-level regions, including 22 provinces, four province-level municipalities (cities) and five province-level autonomous regions. Beijing, Shanghai and Guangdong are also discussed in this report.
The report also highlights developments related to venture capital and corporate investments, regulatory trends and enterprise strategies of key firms and potential future opportunities stemming from AI-driven sequences of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis and tariff assessments makes this report a critical resource for stakeholders, investors and policymakers seeking to understand and take advantage of the rapidly developing Chinese DNA sequencing sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking or share of key companies. It also has a dedicated section of company profiles that covers details of leading companies.
Report Includes
- 16 data tables and 40 additional tables
- Overview and an analysis of the Chinese market for DNA sequencing technologies
- Analyses of the Chinese market trends, with revenue data from 2022-2024, estimates for 2025, and projected CAGRs through 2030
- Estimates of the size and revenue prospects for the market, along with a market share analysis by product and service type, technology, application, end user and provinces
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
- Insights derived from Porter’s Five Forces model and global supply chain analysis
- Discussion of emerging trends and opportunities in next-generation DNA sequencing technologies and applications in research and clinical markets
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of the leading companies, including BGI, Novogene Co. Ltd., Berry Genomics, Annoroad Gene Technology, and Burning Rock Dx.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Landscape
Chapter 8 Appendix
List of Tables
List of Figures
Companies Mentioned
- Agilent Technologies Inc.
- Annoroad Gene Technology
- Berry Genomics
- BGI
- Burning Rock Dx
- Capitalbio Technology Co. Ltd.
- Illumina Inc.
- Novogene Co. Ltd.
- Oxford Nanopore Technologies Plc
- Pacbio
- Thermo Fisher Scientific Inc.
